Global Cost-Effectiveness of Hepatitis C Treatment

Select a Country

Cost Inputs (US Dollars)

Cost of treatment and testing

4-week DAA regimen

Diagnosis of chronic HCV

Assessment of HCV treatment response

Annual cost of health state

F0-F2 fibrosis

F3 fibrosis

Compensated cirrhosis

Decompensated cirrhosis

Liver cancer

Use WHO disability weights to calculate QALYs

Population Profile

Select an age

Fibrosis states distribution

F0 %

F1 %

F2 %

F3 %

Cirrhosis %

Show genotype distribution

The following results show the ICER, the incremental cost-effectiveness ratio, of DAA treatment compared with no treatment. The ICER estimates how much one needs to pay to gain one additional quality-adjusted life year (QALY).

How to interpret the ICER results: ICER below the 3x GDP per capita* of the selected country typically implies cost-effective and negative ICER values (with positive health gains) implies cost-saving.

Incremental cost-effectiveness ratio

HCV-infected persons without cirrhosis:

HCV-Infected persons with cirrhosis:

All patients (with or without cirrhosis):

For each HCV-infected person, DAA treatment (as compared to no treatment) leads to:

Discounted quality-adjusted life years:
Life-time healthcare expenditure:

Figure 1: Discounted QALYs Lived

Figure 2: Total Discounted Lifetime Healthcare Costs

Abbreviations: Tx, treatment; DAA, direct acting anti-viral.

The diagrams below show the number of cases in a cohort of 10,000 HCV-infected persons in a country (with age, and distribution of HCV genotypes and fibrosis stages as specified in the input section) progress to decompensated cirrhosis, liver cancer, or liver-related death over the entire life-time.

* A decline in these estimates means benefit.

Show total number per 10,000 patients throughout life-time

This panel presents the cost-effectiveness of DAA treatment by time. The below figure shows the change of ICER (incremental cost-effectiveness ratio) values with the length of planning horizon. From this figure, we can infer that within how many years, the DAA treatment can be cost-effective, or cost-saving.

How to interpret the ICER results: ICER below the 3x GDP per capita of the selected country typically implies cost-effective and negative ICER values (with positive health gains) implies cost-saving.

Cost-effectiveness of DAA treatment by time horizon